Skip to content
Triangle logo TriangleGet started
← Pancreatic Cancer

NCT01236053 · STUDY IN CONTEXT

Cancer in Patients With Gabapentin (GPRD)

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Incidence of all cancers. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).

Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.

→

primary · POSTED

Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).

Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.

→

primary · POSTED

Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).

Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.

→

primary · POSTED

Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.

Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.

→

primary · POSTED

Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).

Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.

→

primary · POSTED

Incident stomach cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.

Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-pancreatic-cancer
nct id
NCT01236053
trial label
Cancer in Patients With Gabapentin (GPRD)
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
6
harms Count
22
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0000
    source section id
    NCT01236053-om-0000
    source outcome index
    0
    endpoint
    Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
    endpoint definition
    Incidence of all cancers. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).
    time origin
    The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0001
    source section id
    NCT01236053-om-0001
    source outcome index
    1
    endpoint
    Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
    endpoint definition
    Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
    time origin
    The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0002
    source section id
    NCT01236053-om-0002
    source outcome index
    2
    endpoint
    Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
    endpoint definition
    Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
    time origin
    The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0003
    source section id
    NCT01236053-om-0003
    source outcome index
    3
    endpoint
    Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
    endpoint definition
    Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
    time origin
    The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0004
    source section id
    NCT01236053-om-0004
    source outcome index
    4
    endpoint
    Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
    endpoint definition
    Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
    time origin
    The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0005
    source section id
    NCT01236053-om-0005
    source outcome index
    5
    endpoint
    Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
    endpoint definition
    Incident stomach cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
    time origin
    The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Incident All-cancer Patients
    regimen
    Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
    analyzed count
    179138
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01236053-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0000
    arm key
    OG001
    arm label
    Matched Controls for Incident All-cancer Patients
    regimen
    Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
    analyzed count
    1710950
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01236053-om-0000#groups/OG001
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Incident All-cancer Patients
    regimen
    Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
    analyzed count
    179138
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01236053-om-0001#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0001
    arm key
    OG001
    arm label
    Matched Controls for Incident All-cancer Patients
    regimen
    Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
    analyzed count
    1710950
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01236053-om-0001#groups/OG001
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Incident All-cancer Patients
    regimen
    Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
    analyzed count
    179138
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01236053-om-0002#groups/OG000
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0002
    arm key
    OG001
    arm label
    Matched Controls for Incident All-cancer Patients
    regimen
    Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
    analyzed count
    1710950
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01236053-om-0002#groups/OG001
  7. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Incident All-cancer Patients
    regimen
    Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
    analyzed count
    179138
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01236053-om-0003#groups/OG000
  8. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0003
    arm key
    OG001
    arm label
    Matched Controls for Incident All-cancer Patients
    regimen
    Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
    analyzed count
    1710950
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01236053-om-0003#groups/OG001
  9. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0004
    arm key
    OG000
    arm label
    Incident All-cancer Patients
    regimen
    Patients with any type of incident cancer defined from READ/OXMIS codes in the years 1995-2008
    analyzed count
    179138
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01236053-om-0004#groups/OG000
  10. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0004
    arm key
    OG001
    arm label
    Matched Controls for Incident All-cancer Patients
    regimen
    Cancer-free control patients risk set matched with incident all-cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
    analyzed count
    1710950
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01236053-om-0004#groups/OG001
  11. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0005
    arm key
    OG000
    arm label
    Incident Stomach Cancer Patients
    regimen
    Patients with incident stomach cancer defined from READ/OXMIS codes in the years 1995-2008
    analyzed count
    1877
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01236053-om-0005#groups/OG000
  12. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    outcome key
    om-0005
    arm key
    OG001
    arm label
    Matched Controls for Incident Stomach Cancer Patients
    regimen
    Cancer-free control patients risk set matched with incident stomach cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site
    analyzed count
    17853
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01236053-om-0005#groups/OG001
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    harm key
    EG000
    source section id
    NCT01236053-ae
    event group key
    EG000
    event group label
    All-Cancer: Cases
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    Source null
    event definition
    This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    harm key
    EG001
    source section id
    NCT01236053-ae
    event group key
    EG001
    event group label
    All-Cancer: Controls
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    Source null
    event definition
    This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    harm key
    EG002
    source section id
    NCT01236053-ae
    event group key
    EG002
    event group label
    Stomach Cancer: Cases
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    Source null
    event definition
    This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    harm key
    EG003
    source section id
    NCT01236053-ae
    event group key
    EG003
    event group label
    Stomach Cancer: Controls
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    Source null
    event definition
    This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    harm key
    EG004
    source section id
    NCT01236053-ae
    event group key
    EG004
    event group label
    Anal Cancer: Cases
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    Source null
    event definition
    This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    harm key
    EG005
    source section id
    NCT01236053-ae
    event group key
    EG005
    event group label
    Anal Cancer: Controls
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    Source null
    event definition
    This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  7. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    harm key
    EG006
    source section id
    NCT01236053-ae
    event group key
    EG006
    event group label
    Lung Cancer: Cases
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    Source null
    event definition
    This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  8. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    harm key
    EG007
    source section id
    NCT01236053-ae
    event group key
    EG007
    event group label
    Lung Cancer: Controls
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    Source null
    event definition
    This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  9. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    harm key
    EG008
    source section id
    NCT01236053-ae
    event group key
    EG008
    event group label
    Bone/Joint Cancer: Cases
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    Source null
    event definition
    This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  10. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    harm key
    EG009
    source section id
    NCT01236053-ae
    event group key
    EG009
    event group label
    Bone/Joint Cancer: Controls
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    Source null
    event definition
    This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  11. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    harm key
    EG010
    source section id
    NCT01236053-ae
    event group key
    EG010
    event group label
    Breast Cancer: Cases
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    Source null
    event definition
    This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  12. release id
    clinical-indications-draft-1
    disease state id
    ds-pancreatic-cancer
    nct id
    NCT01236053
    harm key
    EG011
    source section id
    NCT01236053-ae
    event group key
    EG011
    event group label
    Breast Cancer: Controls
    serious affected
    0
    serious at risk
    0
    other affected
    0
    other at risk
    0
    frequency threshold
    0
    collection period
    Source null
    event definition
    This is a retrospective study of pre-existing medical record and/or health insurance claims data; all data are de-identified, and thus no assessments of Serious or Non-serious Adverse Events are possible.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice